Squarepoint
SNDX icon

Squarepoint’s Syndax Pharmaceuticals SNDX Stock Holding History

Squarepoint’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,000
Closed -$289K – 5467
2024
Q3 		$289K Buy
+15,000
New +$310K ﹤0.01% 3467

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Squarepoint's SNDX Position: Q1 2026 in Review

Squarepoint increased its Syndax Pharmaceuticals (SNDX) stake by 816% in Q1 2026, buying an estimated $3.51M and bringing the position to 181,552 shares worth $4.24M. The position accounts for 0.01% of the portfolio, ranked #1624.

Squarepoint first reported a position in SNDX in Q4 2017 and has held it in 16 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Squarepoint held 181,552 shares of Syndax Pharmaceuticals worth $4.24M as of Q1 2026.
  • Squarepoint bought 161,738 Syndax Pharmaceuticals shares in Q1 2026, an estimated $3.51M.
  • Syndax Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1624 holding.
  • Squarepoint first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 16 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.